IsoRay Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

false 0000728387 0000728387 2024-01-17 2024-01-17

 

 

 

 

 

 

 

 

 

 

 

Registrant’s telephone number, including area code: (206) 676-0900

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

 

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02         Results of Operations and Financial Condition.

 

On January 17, 2024, Perspective Therapeutics, Inc. (the “Company”) filed, pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), a preliminary prospectus supplement (the “Preliminary Prospectus Supplement”) to its effective registration statement on Form S-3 (File No. 333-275638) with the Securities and Exchange Commission (the “Commission”) in connection with a proposed offering of shares of its common stock, par value $0.001 per share (the “Common Stock”). The Preliminary Prospectus Supplement contains certain information and preliminary estimates regarding the Company’s financial results for the year ended December 31, 2023, which are set forth below.

 

 

 

The preliminary financial data included in this Form 8-K and the Preliminary Prospectus Supplement has been prepared by, and are the responsibility of, the Company’s management. The Company’s independent registered public accounting firm, Assure CPA, LLC, has not audited, reviewed, compiled or performed any procedures with respect to the preliminary financial data. Accordingly, Assure CPA, LLC does not express an opinion or any other form of assurance with respect thereto. The Company’s actual results as of December 31, 2023 may differ from the preliminary financial data due to the completion of the Company’s closing procedures with respect to the fiscal year ended December 31, 2023, final adjustments and other developments that may arise between now and the time the financial results for the fiscal year are finalized.

 

The information furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.